
Claire E Wainwright

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1623792/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Emergence and impact of oprD mutations in Pseudomonas aeruginosa strains in cystic fibrosis. Journal of Cystic Fibrosis, 2022, 21, e35-e43.	0.7	8
2	Cystic Fibrosis Cellular Treatments. , 2022, , 161-178.		0
3	Neutrophil respiratory burst activity is not exaggerated in cystic fibrosis. Journal of Cystic Fibrosis, 2022, 21, 707-712.	0.7	2
4	A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children ≥Â6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variant. Journal of Cystic Fibrosis, 2022, 21, 675-683.	0.7	10
5	Factors in childhood associated with lung function decline to adolescence in cystic fibrosis. Journal of Cystic Fibrosis, 2022, 21, 977-983.	0.7	4
6	Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial. Lancet Respiratory Medicine,the, 2022, 10, 267-277.	10.7	66
7	The effect of inhaled hypertonic saline on lung structure in children aged 3–6 years with cystic fibrosis (SHIP-CT): a multicentre, randomised, double-blind, controlled trial. Lancet Respiratory Medicine,the, 2022, 10, 669-678.	10.7	20
8	The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. Lancet Respiratory Medicine,the, 2022, 10, 776-784.	10.7	14
9	Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for <i>F508del</i> and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 1361-1369.	5.6	50
10	Redesign of the Australian Cystic Fibrosis Data Registry: A multidisciplinary collaboration. Paediatric Respiratory Reviews, 2021, 37, 37-43.	1.8	3
11	A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation. Journal of Cystic Fibrosis, 2021, 20, 68-77.	0.7	37
12	lvacaftor in Infants Aged 4 to <12 Months with Cystic Fibrosis and a Gating Mutation. Results of a Two-Part Phase 3 Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 585-593.	5.6	67
13	Assessing the impact of the 13 valent pneumococcal vaccine on childhood empyema in Australia. Thorax, 2021, 76, 487-493.	5.6	13
14	Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study. Lancet Respiratory Medicine,the, 2021, 9, 733-746.	10.7	33
15	Rapid macrolide and amikacin resistance testing for Mycobacterium abscessus in people with cystic fibrosis. Journal of Medical Microbiology, 2021, 70, .	1.8	4
16	Time to get serious about the detection and monitoring of early lung disease in cystic fibrosis. Thorax, 2021, 76, 1255-1265.	5.6	24
17	Atypical haemolytic uraemic syndrome in a child with cystic fibrosis. Journal of Paediatrics and Child Health, 2021, , .	0.8	0
18	Comparison of midline catheters and peripherally inserted central catheters to reduce the need for general anesthesia in children with respiratory disease: A feasibility randomized controlled trial. Paediatric Anaesthesia, 2021, 31, 985-995.	1.1	7

#	Article	IF	CITATIONS
19	A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One <i>F508del</i> Allele. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 1522-1532.	5.6	146
20	Lumacaftor/ivacaftor reduces exacerbations in adults homozygous for Phe508del mutation with severe lung disease. Journal of Cystic Fibrosis, 2020, 19, 415-420.	0.7	15
21	New therapies for people with CF in the CFTR modulator world. Journal of Cystic Fibrosis, 2020, 19, 669-670.	0.7	2
22	Lung function over the life course of paediatric and adult patients with cystic fibrosis from a large multi-centre registry. Scientific Reports, 2020, 10, 17421.	3.3	26
23	Tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for minimal function CFTR mutations. Journal of Cystic Fibrosis, 2020, 19, 962-968.	0.7	21
24	â€~Go for it, dream big, work hard and persist': A message to the next generation of CF leaders in recognition of International Women's Day 2020. Journal of Cystic Fibrosis, 2020, 19, 184-193.	0.7	3
25	Health-related quality-of-life in children with cystic fibrosis aged 5-years and associations with health outcomes. Journal of Cystic Fibrosis, 2020, 19, 483-491.	0.7	16
26	Total bacterial load, inflammation, and structural lung disease in paediatric cystic fibrosis. Journal of Cystic Fibrosis, 2020, 19, 923-930.	0.7	15
27	Methods for tracking sagebrushâ€steppe community trajectories and quantifying resilience in relation to disturbance and restoration. Restoration Ecology, 2020, 28, 115-126.	2.9	7
28	Centralised versus outreach models of cystic fibrosis care should be tailored to the needs of the individual patient. Internal Medicine Journal, 2020, 50, 232-235.	0.8	0
29	Current infection control practices used in Australian and New Zealand cystic fibrosis centers. BMC Pulmonary Medicine, 2020, 20, 16.	2.0	5
30	Early markers of cystic fibrosis structural lung disease: follow-up of the ACFBAL cohort. European Respiratory Journal, 2020, 55, 1901694.	6.7	14
31	Nontuberculous Mycobacterium. Respiratory Medicine, 2020, , 127-160.	0.1	Ο
32	Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV1. Journal of Cystic Fibrosis, 2019, 18, 94-101.	0.7	36
33	Distinct responses of niche and fitness differences to water availability underlie variable coexistence outcomes in semiâ€arid annual plant communities. Journal of Ecology, 2019, 107, 293-306.	4.0	40
34	Looks can be deceiving: ecologically similar exotics have different impacts on a native competitor. Oecologia, 2019, 190, 927-940.	2.0	2
35	Pseudomonas aeruginosa eradication therapy and risk of acquiring Aspergillus in young children with cystic fibrosis. Thorax, 2019, 74, 740-748.	5.6	15
36	Applied ecological research is on the rise but connectivity barriers persist between four major subfields. Journal of Applied Ecology, 2019, 56, 1492-1498.	4.0	13

#	Article	IF	CITATIONS
37	Increased susceptibility of airway epithelial cells from ataxia-telangiectasia to S. pneumoniae infection due to oxidative damage and impaired innate immunity. Scientific Reports, 2019, 9, 2627.	3.3	21
38	Improved Clinical Outcome After Treatment of Mycobacterium abscessus Complex Pulmonary Disease in Children With Cystic Fibrosis. Pediatric Infectious Disease Journal, 2019, 38, 660-666.	2.0	4
39	Differential expression of genes and receptors in monocytes from patients with cystic fibrosis. Journal of Cystic Fibrosis, 2019, 18, 342-348.	0.7	17
40	Multiâ€centre ethics and research governance review can impede nonâ€interventional clinical research. Internal Medicine Journal, 2019, 49, 722-728.	0.8	11
41	Mutations in the HFE gene can be associated with increased lung disease severity in cystic fibrosis. Gene, 2019, 683, 12-17.	2.2	6
42	Aspergillus and progression of lung disease in children with cystic fibrosis. Thorax, 2019, 74, 125-131.	5.6	32
43	Cystic fibrosis pathogens survive for extended periods within cough-generated droplet nuclei. Thorax, 2019, 74, 87-90.	5.6	23
44	Cyclic population dynamics and densityâ€dependent intransitivity as pathways to coexistence between coâ€occurring annual plants. Journal of Ecology, 2018, 106, 838-851.	4.0	25
45	Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis, 2018, 17, 83-88.	0.7	36
46	Links between community ecology theory and ecological restoration are on the rise. Journal of Applied Ecology, 2018, 55, 570-581.	4.0	74
47	Face Masks and Cough Etiquette Reduce the Cough Aerosol Concentration of <i>Pseudomonas aeruginosa</i> in People with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 348-355.	5.6	48
48	Pooling of bronchoalveolar lavage in children with cystic fibrosis does not adversely affect the microbiological yield or sensitivity in detecting pulmonary inflammation. Journal of Cystic Fibrosis, 2018, 17, 391-399.	0.7	4
49	Bronchoscopy-guided antimicrobial therapy for cystic fibrosis. The Cochrane Library, 2018, 9, CD009530.	2.8	7
50	Expression of Pseudomonas aeruginosa Antibiotic Resistance Genes Varies Greatly during Infections in Cystic Fibrosis Patients. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	21
51	Face Masks Reduce the Release of <i>Pseudomonas aeruginosa</i> Cough Aerosols When Worn for Clinically Relevant Periods. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1339-1342.	5.6	34
52	Evaluating the impact of 2006 Australasian Clinical Practice Guidelines for nutrition in children with cystic fibrosis in Australia. Respiratory Medicine, 2018, 142, 7-14.	2.9	8
53	lvacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study. Lancet Respiratory Medicine,the, 2018, 6, 545-553.	10.7	205
54	Inhaled Corticosteroids and Respiratory Infections in Children With Asthma: A Meta-analysis. Pediatrics, 2017, 139, .	2.1	22

#	Article	IF	CITATIONS
55	Loss of ATM in Airway Epithelial Cells Is Associated with Susceptibility to Oxidative Stress. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 391-393.	5.6	18
56	CFTR-dependent defect in alternatively-activated macrophages in cystic fibrosis. Journal of Cystic Fibrosis, 2017, 16, 475-482.	0.7	57
57	Year in review 2016: Interstitial lung disease, pulmonary vascular disease, pulmonary function, paediatric lung disease, cystic fibrosis and sleep. Respirology, 2017, 22, 1022-1034.	2.3	2
58	New treatments targeting the basic defects in cystic fibrosis. Presse Medicale, 2017, 46, e165-e175.	1.9	36
59	Preserving Lung Function: The Holy Grail in Managing Cystic Fibrosis. Annals of the American Thoracic Society, 2017, 14, 833-835.	3.2	10
60	Efficacy and safety of lumacaftor and ivacaftor in patients aged 6–11 years with cystic fibrosis homozygous for F508del-CFTR : a randomised, placebo-controlled phase 3 trial. Lancet Respiratory Medicine,the, 2017, 5, 557-567.	10.7	243
61	Sources and dynamics of fluorescent particles in hospitals. Indoor Air, 2017, 27, 988-1000.	4.3	30
62	Particle and bioaerosol characteristics in a paediatric intensive care unit. Environment International, 2017, 107, 89-99.	10.0	25
63	Effects of exotic annual grass litter and local environmental gradients on annual plant community structure. Biological Invasions, 2017, 19, 479-491.	2.4	16
64	The changing prevalence of pulmonary infection in adults with cystic fibrosis: A longitudinal analysis. Journal of Cystic Fibrosis, 2017, 16, 70-77.	0.7	34
65	Nebulised hypertonic saline solution for acute bronchiolitis in infants. The Cochrane Library, 2017, 2017, 2017, CD006458.	2.8	57
66	Targeted therapy for chronic respiratory disease: a new paradigm. Medical Journal of Australia, 2017, 206, 136-140.	1.7	7
67	A Novel Method and Its Application to Measuring Pathogen Decay in Bioaerosols from Patients with Respiratory Disease. PLoS ONE, 2016, 11, e0158763.	2.5	20
68	Bronchoscopy-guided antimicrobial therapy for cystic fibrosis. The Cochrane Library, 2016, , CD009530.	2.8	17
69	Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis. Lancet Respiratory Medicine,the, 2016, 4, 617-626.	10.7	129
70	Alterations of the Nasopharyngeal Microbiota in Infants with Cystic Fibrosis. Cystic Fibrosis Transmembrane Conductance Regulator and Antibiotic Effects. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 473-474.	5.6	1
71	<scp><i>P</i></scp> <i>seudomonas aeruginosa</i> antibiotic resistance in <scp>A</scp> ustralian cystic fibrosis centres. Respirology, 2016, 21, 329-337.	2.3	43
72	Year in review 2015: Interstitial lung disease, pulmonary vascular disease, pulmonary function, sleep and ventilation, cystic fibrosis and paediatric lung disease. Respirology, 2016, 21, 556-566.	2.3	4

#	Article	IF	CITATIONS
73	Therapeutic targets and investigated treatments for Ataxia-Telangiectasia. Expert Opinion on Orphan Drugs, 2016, 4, 1263-1276.	0.8	4
74	Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium. Science, 2016, 354, 751-757.	12.6	462
75	Diagnosis and early life risk factors for bronchiectasis in cystic fibrosis: a review. Expert Review of Respiratory Medicine, 2016, 10, 1003-1010.	2.5	15
76	A systematic review of studies examining the rate of lung function decline in patients with cystic fibrosis. Paediatric Respiratory Reviews, 2016, 20, 55-66.	1.8	77
77	Response to: â€`Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?' by Jones and Barry. Thorax, 2016, 71, 185-186.	5.6	6
78	Using the General Level Framework to guide training and development needs of pharmacists working in paediatrics. Journal of Pharmacy Practice and Research, 2015, 45, 322-330.	0.8	4
79	What does advanced practice mean to Australian paediatric pharmacists? A focus group study. International Journal of Pharmacy Practice, 2015, 23, 141-149.	0.6	3
80	Genotypic Diversity within a Single Pseudomonas aeruginosa Strain Commonly Shared by Australian Patients with Cystic Fibrosis. PLoS ONE, 2015, 10, e0144022.	2.5	17
81	Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del <i>CFTR</i> . New England Journal of Medicine, 2015, 373, 220-231.	27.0	1,308
82	Pseudomonas aeruginosa genotypes acquired by children with cystic fibrosis by age 5-years. Journal of Cystic Fibrosis, 2015, 14, 361-369.	0.7	61
83	Climate moderates release from nutrient limitation in natural annual plant communities. Global Ecology and Biogeography, 2015, 24, 549-561.	5.8	47
84	Asteraceae invaders have limited impacts on the pollination of common native annual species in SW Western Australia's open woodland wildflower communities. Plant Ecology, 2015, 216, 1103-1115.	1.6	4
85	The social network of cystic fibrosis centre care and shared Pseudomonas aeruginosa strain infection: a cross-sectional analysis. Lancet Respiratory Medicine,the, 2015, 3, 640-650.	10.7	26
86	Nebulized Hypertonic Saline for Acute Bronchiolitis: A Systematic Review. Pediatrics, 2015, 136, 687-701.	2.1	72
87	Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del <i>CFTR</i> . New England Journal of Medicine, 2015, 373, 1783-1784.	27.0	196
88	Oxygen saturation targets in infants with bronchiolitis. Lancet, The, 2015, 386, 1016-1018.	13.7	6
89	Comparative genomics of non-pseudomonal bacterial species colonising paediatric cystic fibrosis patients. PeerJ, 2015, 3, e1223.	2.0	35
90	Ivacaftor for patients with cystic fibrosis. Expert Review of Respiratory Medicine, 2014, 8, 533-538.	2.5	20

#	Article	IF	CITATIONS
91	Viability of <i>Pseudomonas aeruginosa</i> in cough aerosols generated by persons with cystic fibrosis. Thorax, 2014, 69, 740-745.	5.6	79
92	Year in review 2013: Lung cancer, respiratory infections, tuberculosis, cystic fibrosis, pleural diseases, bronchoscopic intervention and imaging. Respirology, 2014, 19, 448-460.	2.3	5
93	Realising opportunities for evidence-based cancer service delivery and research: linking cancer registry and administrative data in Australia. European Journal of Cancer Care, 2014, 23, 721-727.	1.5	17
94	Characteristics of adverse medication events in a children's hospital. Journal of Paediatrics and Child Health, 2014, 50, 966-971.	0.8	4
95	Safety of inhaled (Tobi®) and intravenous tobramycin in young children with cystic fibrosis. Journal of Cystic Fibrosis, 2014, 13, 428-434.	0.7	17
96	Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST). Lancet Respiratory Medicine,the, 2014, 2, 902-910.	10.7	191
97	Costs of Bronchoalveolar Lavage-Directed Therapy in the First 5ÂYears of Life for Children with Cystic Fibrosis. Journal of Pediatrics, 2014, 165, 564-569.e5.	1.8	16
98	A comparison of two informative SNP-based strategies for typing Pseudomonas aeruginosa isolates from patients with cystic fibrosis. BMC Infectious Diseases, 2014, 14, 307.	2.9	20
99	Electronic care records — Can they fulfil their promise?. Journal of Cystic Fibrosis, 2014, 13, 608-609.	0.7	1
100	Efficacy and Safety of Ivacaftor in Patients Aged 6 to 11 Years with Cystic Fibrosis with a <i>G551D</i> Mutation. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 1219-1225.	5.6	449
101	Bronchoscopy-guided antimicrobial therapy for cystic fibrosis. , 2013, , CD009530.		13
102	Exotic species display greater germination plasticity and higher germination rates than native species across multiple cues. Biological Invasions, 2013, 15, 2253-2264.	2.4	99
103	Nebulised hypertonic saline solution for acute bronchiolitis in infants. The Cochrane Library, 2013, , CD006458.	2.8	137
104	High-throughput single-nucleotide polymorphism-based typing of shared Pseudomonas aeruginosa strains in cystic fibrosis patients using the Sequenom iPLEX platform. Journal of Medical Microbiology, 2013, 62, 734-740.	1.8	9
105	Virulence factor expression patterns in Pseudomonas aeruginosa strains from infants with cystic fibrosis. European Journal of Clinical Microbiology and Infectious Diseases, 2013, 32, 1583-1592.	2.9	23
106	Type 3 secretion system effector genotype and secretion phenotype of longitudinally collected Pseudomonas aeruginosa isolates from young children diagnosed with cystic fibrosis following newborn screening. Clinical Microbiology and Infection, 2013, 19, 266-272.	6.0	19
107	Pulmonary exacerbations as indicators of progression of lung disease in young children with CF. Thorax, 2013, 68, 608-609.	5.6	6
108	Shared <i>Pseudomonas aeruginosa</i> genotypes are common in Australian cystic fibrosis centres. European Respiratory Journal, 2013, 41, 1091-1100.	6.7	59

#	Article	IF	CITATIONS
109	Prospective evaluation of respiratory exacerbations in children with cystic fibrosis from newborn screening to 5â€years of age. Thorax, 2013, 68, 643-651.	5.6	83
110	Factors Influencing Acquisition of Burkholderia cepacia Complex Organisms in Patients with Cystic Fibrosis. Journal of Clinical Microbiology, 2013, 51, 3975-3980.	3.9	33
111	Long term effects of denufosol tetrasodium in patients with cystic fibrosis. Journal of Cystic Fibrosis, 2012, 11, 539-549.	0.7	85
112	Comparison of DNA Extraction Methods for Microbial Community Profiling with an Application to Pediatric Bronchoalveolar Lavage Samples. PLoS ONE, 2012, 7, e34605.	2.5	126
113	Pleural fluid nucleic acid testing enhances pneumococcal surveillance in children. Respirology, 2012, 17, 114-119.	2.3	18
114	Seasonal priority effects: implications for invasion and restoration in a semiâ€arid system. Journal of Applied Ecology, 2012, 49, 234-241.	4.0	141
115	Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa. Journal of Cystic Fibrosis, 2011, 10, 234-242.	0.7	86
116	Bacterial Causes of Empyema in Children, Australia, 2007–2009. Emerging Infectious Diseases, 2011, 17, 1839-1845.	4.3	46
117	Effect of Bronchoalveolar Lavage–Directed Therapy on Pseudomonas aeruginosa Infection and Structural Lung Injury in Children With Cystic Fibrosis. JAMA - Journal of the American Medical Association, 2011, 306, 163-71.	7.4	170
118	Treatment of cystic fibrosis following infant screening. Therapy: Open Access in Clinical Medicine, 2011, 8, 613-622.	0.2	3
119	Yearâ€inâ€review 2010: Asthma, COPD, cystic fibrosis and airway biology. Respirology, 2011, 16, 540-552.	2.3	5
120	Pneumonia in the first 2 years of life, and asthma in preschoolâ€age children. Pediatrics International, 2011, 53, 576-580.	0.5	11
121	Rapid single-nucleotide polymorphism-based identification of clonal Pseudomonas aeruginosa isolates from patients with cystic fibrosis by the use of real-time PCR and high-resolution melting curve analysis. Clinical Microbiology and Infection, 2011, 17, 1403-1408.	6.0	12
122	A bedside assay to detect <i>streptococcus pneumoniae</i> in children with empyema. Pediatric Pulmonology, 2011, 46, 179-183.	2.0	14
123	Bronchoalveolar Lavage–Directed Therapy in Children With Cystic Fibrosis and <emph type="ital">Pseudomonas aeruginosa Infection—Reply. JAMA - Journal of the American Medical Association, 2011, 306, 1761.</emph 	7.4	0
124	A CFTR Potentiator in Patients with Cystic Fibrosis and the <i>G551D</i> Mutation. New England Journal of Medicine, 2011, 365, 1663-1672.	27.0	1,920
125	Effect of Temperature on Cystic Fibrosis Lung Disease and Infections: A Replicated Cohort Study. PLoS ONE, 2011, 6, e27784.	2.5	87
126	Acute viral bronchiolitis in children- a very common condition with few therapeutic options. Paediatric Respiratory Reviews, 2010, 11, 39-45.	1.8	102

#	Article	IF	CITATIONS
127	Cochrane review: Nebulized hypertonic saline solution for acute bronchiolitis in infants. Evidence-Based Child Health: A Cochrane Review Journal, 2010, 5, 1251-1273.	2.0	0
128	Asthma and insulin resistance in children. Respirology, 2010, 15, 779-784.	2.3	79
129	Seasonal priority effects: Implications for invasion and restoration in California coastal sage scrub. Nature Precedings, 2010, , .	0.1	0
130	Value of serology in predicting Pseudomonas aeruginosa infection in young children with cystic fibrosis. Thorax, 2010, 65, 985-990.	5.6	34
131	A Randomized Controlled Trial of an Interactive Voice Response Telephone System and Specialist Nurse Support for Childhood Asthma Management. Journal of Asthma, 2010, 47, 768-773.	1.7	22
132	SegniliparusrugosusInfection, Australia. Emerging Infectious Diseases, 2009, 15, 611-613.	4.3	17
133	Low Rates of Pseudomonas aeruginosa Misidentification in Isolates from Cystic Fibrosis Patients. Journal of Clinical Microbiology, 2009, 47, 1503-1509.	3.9	52
134	Determination of the Minimal Clinically Important Difference Scores for the Cystic Fibrosis Questionnaire-Revised Respiratory Symptom Scale in Two Populations of Patients With Cystic Fibrosis and Chronic Pseudomonas aeruginosa Airway Infection. Chest, 2009, 135, 1610-1618.	0.8	353
135	Genetic Modifiers of Liver Disease in Cystic Fibrosis. JAMA - Journal of the American Medical Association, 2009, 302, 1076.	7.4	256
136	Identification of Pseudomonas aeruginosa by a duplex real-time polymerase chain reaction assay targeting the ecfX and the gyrB genes. Diagnostic Microbiology and Infectious Disease, 2009, 63, 127-131.	1.8	90
137	Cough-generated aerosols of Pseudomonas aeruginosa and other Gram-negative bacteria from patients with cystic fibrosis. Thorax, 2009, 64, 926-931.	5.6	122
138	The Long Term Efficacy of Gastrostomy Feeding in Children with Cystic Fibrosis on Anthropometric Markers of Nutritonal Status and Pulmonary Function. Open Respiratory Medicine Journal, 2009, 3, 112-115.	0.4	25
139	Safety of bronchoalveolar lavage in young children with cystic fibrosis. Pediatric Pulmonology, 2008, 43, 965-972.	2.0	48
140	Nebulized hypertonic saline solution for acute bronchiolitis in infants. , 2008, , CD006458.		111
141	Disease surveillance using bronchoalveolar lavage. Paediatric Respiratory Reviews, 2008, 9, 151-159.	1.8	53
142	High prevalence of a class 1 integron-associated aadB gene cassette in Pseudomonas aeruginosa isolates from an Australian cystic fibrosis patient population. Pathology, 2008, 40, 524-525.	0.6	2
143	Infants with chronic neonatal lung disease: recommendations for the use of home oxygen therapy. Medical Journal of Australia, 2008, 189, 578-582.	1.7	52
144	Clinical outcomes of Queensland children with cystic fibrosis: a comparison between tertiary centre and outreach services. Medical Journal of Australia, 2008, 188, 135-139.	1.7	23

#	Article	IF	CITATIONS
145	Daily versus weekly azithromycin in cystic fibrosis patients. European Respiratory Journal, 2007, 30, 487-495.	6.7	55
146	Phenotypic Characterization of Clonal and Nonclonal Pseudomonas aeruginosa Strains Isolated from Lungs of Adults with Cystic Fibrosis. Journal of Clinical Microbiology, 2007, 45, 1697-1704.	3.9	100
147	Novel Neutrophil-Derived Proteins in Bronchoalveolar Lavage Fluid Indicate an Exaggerated Inflammatory Response in Pediatric Cystic Fibrosis Patients. Clinical Chemistry, 2007, 53, 1782-1791.	3.2	45
148	Fosfomycin – Investigation of a possible new route of administration of an old drug. Journal of Cystic Fibrosis, 2007, 6, 244-246.	0.7	17
149	A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients. British Journal of Clinical Pharmacology, 2007, 63, 438-450.	2.4	45
150	Population Pharmacokinetics of Itraconazole and its Active Metabolite Hydroxy-Itraconazole in Paediatric Cystic Fibrosis and Bone Marrow Transplant Patients. Clinical Pharmacokinetics, 2006, 45, 1099-1114.	3.5	54
151	Quality-of-life in children and adolescents with cystic fibrosis managed in both regional outreach and cystic fibrosis center settings in queensland. Journal of Pediatrics, 2006, 148, 508-516.e1.	1.8	32
152	The nutritional status of children with cystic fibrosis. British Journal of Nutrition, 2006, 95, 321-324.	2.3	10
153	Controlled longitudinal study of bone mass accrual in children and adolescents with cystic fibrosis. Thorax, 2006, 61, 146-154.	5.6	75
154	Protease IV production in Pseudomonas aeruginosa from the lungs of adults with cystic fibrosis. Journal of Medical Microbiology, 2006, 55, 1641-1644.	1.8	28
155	Misleading High Tobramycin Plasma Concentrations Can Be Caused by Skin Contamination of Fingerprick Blood Following Inhalation of Nebulized Tobramycin (TOBI??). Therapeutic Drug Monitoring, 2005, 27, 205-207.	2.0	10
156	Pubertal development and its influences on bone mineral density in Australian children and adolescents with cystic fibrosis. Journal of Paediatrics and Child Health, 2005, 41, 317-322.	0.8	33
157	Diagnosis of cystic fibrosis after newborn screening: The Australasian experience?twenty years and five million babies later: A consensus statement from the Australasian paediatric respiratory group. Pediatric Pulmonology, 2005, 39, 440-446.	2.0	79
158	A Clinical Pathway for Bronchiolitis is Effective in Reducing Readmission Rates. Journal of Pediatrics, 2005, 147, 622-626.	1.8	58
159	Sensitivity of respiratory bacteria to lignocaine. Pathology, 2005, 37, 305-307.	0.6	10
160	Clonal strains of Pseudomonas aeruginosa in paediatric and adult cystic fibrosis units. European Respiratory Journal, 2004, 24, 101-106.	6.7	113
161	Bone mineral density in Australian children, adolescents and adults with cystic fibrosis: a controlled cross sectional study. Thorax, 2004, 59, 149-155.	5.6	138
162	The use of air displacement plethysmography in children and adolescents with cystic fibrosis. European Journal of Clinical Nutrition, 2004, 58, 985-989.	2.9	9

#	Article	IF	CITATIONS
163	Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. Journal of Cystic Fibrosis, 2004, 3, 67-91.	0.7	265
164	Vitamin A levels in patients with CF are influenced by the inflammatory response. Journal of Cystic Fibrosis, 2004, 3, 143-149.	0.7	36
165	Total body water in children with cystic fibrosis using bioelectrical impedance. Journal of Cystic Fibrosis, 2004, 3, 243-247.	0.7	10
166	Rapid genotyping of Pseudomonas aeruginosa isolates harboured by adult and paediatric patients with cystic fibrosis using repetitive-element-based PCR assays. Journal of Medical Microbiology, 2004, 53, 1089-1096.	1.8	102
167	Abnormalities of the PTH-vitamin D axis and bone turnover markers in children, adolescents and adults with cystic fibrosis: comparison with healthy controls. Osteoporosis International, 2003, 14, 404-411.	3.1	57
168	A Multicenter, Randomized, Double-Blind, Controlled Trial of Nebulized Epinephrine in Infants with Acute Bronchiolitis. New England Journal of Medicine, 2003, 349, 27-35.	27.0	229
169	A Review of Telemedicine and Asthma. Disease Management and Health Outcomes, 2003, 11, 557-563.	0.4	12
170	Evidence for Spread of a Clonal Strain of Pseudomonas aeruginosa among Cystic Fibrosis Clinics. Journal of Clinical Microbiology, 2003, 41, 2266-2267.	3.9	81
171	Treatment of Bronchiolitis. New England Journal of Medicine, 2003, 349, 1384-1385.	27.0	1
172	Early airway infection, inflammation, and lung function in cystic fibrosis. Archives of Disease in Childhood, 2002, 87, 306-311.	1.9	108
173	Series of laryngomalacia, tracheomalacia, and bronchomalacia disorders and their associations with other conditions in children. Pediatric Pulmonology, 2002, 34, 189-195.	2.0	154
174	8. Asthma in children. Medical Journal of Australia, 1997, 167, 218-223.	1.7	22
175	Resting energy expenditure, pulmonary inflammation, and genotype in the early course of cystic fibrosis. Journal of Pediatrics, 1996, 129, 367-373.	1.8	65
176	Diverse outcomes of species interactions in an invaded annual plant community. Journal of Plant Ecology, 0, , rtw102.	2.3	4